相关实验视频

Updated: Sep 9, 2025

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

在先前用抗VEGF疗法治疗的神经血管与年龄相关的黄斑退化时,法里西马布对视觉敏度和视网膜结构的影响

Nathan Sattah¹, Wufan Zhao¹, Alex Choi¹

¹School of Medicine, Duke University, Durham, NC, USA.

Journal of vitreoretinal diseases

|September 2, 2025

概括

转换为法里西马布治疗新血管与年龄相关的黄斑变性 (nAMD) 减少了视网膜厚度,但导致了更多的注射和视力丧失. 这些抗VEGF疗法需要进一步研究.

科学领域:

眼科眼科
视网膜疾病
药理学

背景情况:

与年龄相关的新血管性黄斑退化 (nAMD) 是导致视力丧失的主要原因.
传统的抗VEGF疗法是对nAMD的标准治疗方法.
法里西马布是一种针对VEGF和血管蛋白-2的新型双特异抗体.

研究的目的:

评估在nAMD患者中从已有的抗VEGF治疗转换为法里西马布的疗效和安全性.
评估视觉敏度,视网膜厚度和注射频率的变化.

主要方法:

从68名nAMD患者中对84个眼睛进行了回顾,这些患者先前接受过贝瓦西祖马布,拉尼比祖马布或阿弗利伯塞普的治疗.
开始服用法里西马布前一年和开始服用法里西马布后6-12个月的结果比较.
对中央斑点厚度 (CMT) 和视力敏度 (VA) 的光学连贯性断层扫描 (OCT) 的分析.

主要成果:

法里西马布治疗导致平均CMT显著降低 (282. 3至244. 8μm;P< 0. 01).
年内注射频率从7. 73增加到8. 66 (P<. 001).
在开始服用法里西马布前,视力没有显著变化,但在开始服用法里西马布后,视力有所下降 (P < 0.01),其中4只眼睛出现斑点缩 (P < 0.01).

结论:

在先前接受抗VEGF治疗的nAMD患者中,切换为法里西马布可以减少视网膜厚度.
然而,这种转换可能与注射频率的增加,视力敏度的下降以及斑点缩的发展有关.
需要进行更大规模的研究来进一步研究这些发现以及法里西马布的长期安全性.

关键词:

对抗VEGF的药物法里西马布新血管与年龄相关的斑点退化

更多相关视频

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...